Parissis John, Georgiou Christos, Bistola Vasiliki, Karavidas Apostolos, Vassilikos Vassilios P, Kanakakis John, Davlouros Periklis, Tziakas Dimitrios N, Alexanian Ioannis P, Kochiadakis George, Triposkiadis Filippos, Karvounis Haralambos, Gourlis Dimitrios, Papoutsidakis Nikolaos, Polyzogopoulou Effie, Vlachopoulos Charalambos
Emergency Medicine Department, Attikon University Hospital, National and Kapodistrian University of Athens, Rimini 1, Chaidari, 12461 Athens, Greece.
Heart Failure Unit, 2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Rimini 1, Chaidari, 12461 Athens, Greece.
J Clin Med. 2023 Sep 30;12(19):6319. doi: 10.3390/jcm12196319.
(1) Background: Patients with diabetes mellitus (DM) are at increased risk for heart failure (HF). Accurate data regarding the prevalence of HF stages among diabetics in Greece are scarce. (2) Aim: The present study will examine the prevalence and evolution of HF stages among patients with type II DM (T2DM) diagnosed in the past 10 years, with no previous history of HF and at high CV risk, in Greece, as well as will explore the potential determinants of the development of symptomatic HF in these patients. (3) Methods: Through a non-interventional, epidemiological, single-country, multi-center, prospective cohort study design, a sample of 300 consecutive patients will be enrolled in 11 cardiology departments that are HF centers of excellence. Patients will be either self-referred or referred by primary or secondary care physicians and will be followed for up to 24 months. Demographic, clinical, echocardiography, electrocardiography, cardiac biomarkers (troponin, NT-proBNP) and health-related quality of life questionnaire data will be recorded as well as clinical events, including mortality, HF hospitalizations and HF-related healthcare resource utilization. The primary outcomes are the proportion of patients diagnosed with symptomatic HF (ACC/AHA Stage C) at enrolment in the overall study population and the proportions of patients with HF stages A, B and C, as well as by NYHA functional classification in the overall study population. (4) Conclusions: The HF-LanDMark study is the first epidemiological study that will assess the prevalence of HF among T2DM patients in Greece that could potentially enhance prompt therapeutic interventions shown to delay the development of HF in the T2DM patient population (HF-LanDMark, Clinical Trials.gov number, NCT04482283).
(1) 背景：糖尿病（DM）患者发生心力衰竭（HF）的风险增加。希腊关于糖尿病患者中HF各阶段患病率的准确数据稀缺。(2) 目的：本研究将调查希腊过去10年诊断的II型糖尿病（T2DM）患者中HF各阶段的患病率及演变情况，这些患者既往无HF病史且心血管风险高，同时还将探索这些患者发生症状性HF的潜在决定因素。(3) 方法：通过一项非干预性、流行病学、单国家、多中心、前瞻性队列研究设计，在11个作为卓越HF中心的心脏病学科室纳入300例连续患者的样本。患者将自行转诊或由初级或二级保健医生转诊，并将随访长达24个月。记录人口统计学、临床、超声心动图、心电图、心脏生物标志物（肌钙蛋白、NT-proBNP）及健康相关生活质量问卷数据，以及临床事件，包括死亡率、HF住院情况和与HF相关的医疗资源利用情况。主要结局是在整个研究人群中入组时诊断为症状性HF（ACC/AHA C期）的患者比例，以及整个研究人群中HF A、B和C期患者的比例，以及按NYHA功能分级的比例。(4) 结论：HF-LanDMark研究是第一项评估希腊T2DM患者中HF患病率的流行病学研究，这可能会加强已证明可延缓T2DM患者人群中HF发生的及时治疗干预措施（HF-LanDMark，临床试验.gov编号，NCT04482283）。
